Literature DB >> 24472710

Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.

Zachary D Reardon1, Sanjay G Patel2, Harras B Zaid3, C J Stimson3, Matthew J Resnick4, Kirk A Keegan5, Daniel A Barocas6, Sam S Chang3, Michael S Cookson7.   

Abstract

BACKGROUND: Despite the documented survival benefit conferred by neoadjuvant (NAC) and adjuvant chemotherapy (AC), there has been a slow adoption of guideline recommendations for the use of perioperative chemotherapy (POC) in patients with muscle-invasive bladder cancer (MIBC).
OBJECTIVE: To evaluate temporal trends in POC utilization and identify factors influencing POC delivery in a representative cohort of patients with MIBC. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study identifying factors associated with receipt of POC and evaluating temporal changes in NAC and AC utilization. We included patients from the National Cancer Data Base (NCDB) with no prior malignancy who ultimately underwent radical cystectomy for ≥ cT2/cN0/cM0 MIBC between 2006 and 2010. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships between demographic and hospital factors and the likelihood of receiving POC were evaluated using Pearson chi-square and Wilcoxon rank-sum tests, and multivariable logistic regression. Temporal changes in NAC and AC use were detected using a linear test of trend. RESULTS AND LIMITATIONS: A total of 5692 patients met our inclusion criteria. POC use increased from 29.5% in 2006 to 39.8% in 2010 (p < 0.001). NAC use increased from 10.1% in 2006 to 20.8% in 2010 (p = 0.005); AC remained stable between 18.1% and 21.3% (p = 0.68). Multivariable modeling revealed advanced age, increasing comorbidity, lack of insurance, increased travel distance, geographic location outside the northeastern United States, and lower income as negatively associated with POC receipt (all p < 0.05). Limitations include retrospective design and potential sampling bias, excluding patients treated at non-NCDB facilities.
CONCLUSIONS: POC use for MIBC increased from 2006 to 2010, with this increase disproportionately due to rising NAC utilization. Nonetheless, there is persistent variation in the likelihood of receiving POC secondary to nonclinical factors. PATIENT
SUMMARY: When retrospectively analyzing a representative cohort of patients undergoing radical cystectomy for muscle-invasive bladder cancer between 2006 and 2010, we noted that preoperative chemotherapy rates increased steadily while use of chemotherapy after surgery remained stable. Factors related to access to care significantly influenced receipt of chemotherapy.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Bladder cancer; Drug therapy; Neoadjuvant therapy; Review

Mesh:

Substances:

Year:  2014        PMID: 24472710      PMCID: PMC4469385          DOI: 10.1016/j.eururo.2014.01.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Authors:  Atreya Dash; Matthew D Galsky; Andrew J Vickers; Angel M Serio; Theresa M Koppie; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

2.  A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program.

Authors:  C J Mettlin; H R Menck; D P Winchester; G P Murphy
Journal:  Cancer       Date:  1997-05-15       Impact factor: 6.860

3.  The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.

Authors:  A Bamias; E Efstathiou; L A Moulopoulos; D Gika; G Hamilos; M P Zorzou; C Kakoyiannis; E Kastritis; G Bozas; C Papadimitriou; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

4.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

5.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Authors:  Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

6.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Authors:  Kevin A David; Matthew I Milowsky; Jamie Ritchey; Peter R Carroll; David M Nanus
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450

9.  Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older.

Authors:  Brent K Hollenbeck; David C Miller; David Taub; Rodney L Dunn; Willie Underwood; James E Montie; John T Wei
Journal:  Urology       Date:  2004-08       Impact factor: 2.649

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  72 in total

1.  Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy.

Authors:  Uros Milenkovic; Murat Akand; Lisa Moris; Liesbeth Demaegd; Tim Muilwijk; Youri Bekhuis; Annouschka Laenen; Ben Van Cleynenbreugel; Wouter Everaerts; Hein Van Poppel; Herlinde Dumez; Maarten Albersen; Steven Joniau
Journal:  World J Urol       Date:  2018-12-05       Impact factor: 4.226

Review 2.  Bladder cancer in 2015: Improving indication, technique and outcome of radical cystectomy.

Authors:  J Alfred Witjes
Journal:  Nat Rev Urol       Date:  2015-11-24       Impact factor: 14.432

3.  Re: The feasibility of radical cystectomy in elderly patients.

Authors:  Öner Şanlı; Abubekir Böyük
Journal:  Turk J Urol       Date:  2014-03

4.  Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; M Sarah Rose; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

5.  Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Authors:  Matthew R Danzig; Katherine Mallin; James M McKiernan; Walter M Stadler; Srikala S Sridhar; Todd M Morgan; Bernard H Bochner; Cheryl T Lee
Journal:  Cancer       Date:  2018-04-06       Impact factor: 6.860

6.  Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer.

Authors:  Felix V Chen; Tulay Koru-Sengul; Feng Miao; Joshua S Jue; Mahmoud Alameddine; Devina J Dave; Sanoj Punnen; Dipen J Parekh; Chad R Ritch; Mark L Gonzalgo
Journal:  Urol Oncol       Date:  2019-08-14       Impact factor: 3.498

Review 7.  Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.

Authors:  Ming Yin; Monika Joshi; Richard P Meijer; Michael Glantz; Sheldon Holder; Harold A Harvey; Matthew Kaag; Elisabeth E Fransen van de Putte; Simon Horenblas; Joseph J Drabick
Journal:  Oncologist       Date:  2016-04-06

8.  A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.

Authors:  Ettore Di Trapani; Rafael Sanchez-Salas; Giorgio Gandaglia; Lorenzo Rocchini; Marco Moschini; Daphne Lizee; Arie Carneiro; Arjun Sivaraman; Eric Barret; François Rozet; Marc Galiano; Mostefa Bennamoun; Renzo Colombo; Nazareno Suardi; Alberto Briganti; Francesco Montorsi; Xavier Cathelineau
Journal:  World J Urol       Date:  2015-07-22       Impact factor: 4.226

9.  The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma.

Authors:  Umang Swami; Petros Grivas; Neeraj Agarwal
Journal:  Oncologist       Date:  2019-03-29

10.  Bladder Cancer Academy 2018 Selected Summaries.

Authors:  Nermarie Velázquez
Journal:  Rev Urol       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.